EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab By Ogkologos - October 23, 2025 368 0 Facebook Twitter Google+ Pinterest WhatsApp It adopted a new route for administration along with a new pharmaceutical form Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Imlunestrant Improves PFS Among Patients with ESR1-mutated ER-positive, HER2-negative ABC and... December 17, 2024 England slips further off-track for smokefree 2030 target December 29, 2022 FDA Oversight of E-Cigarettes Gathers Speed: A Conversation with Mitch Zeller January 5, 2022 FDA Approves Device for Treatment of Osteoid Osteoma in the Extremities December 1, 2020 Load more HOT NEWS Cancer in My Community: Striving to Lead People to Cancer Care... New drug available for rare thyroid cancer on NHS in England RANO and Modified RANO Criteria Demonstrate Similar Correlations Between PFS and... Ensartinib Improves DFS Outcomes in Patients with ALK-positive, Completely Resected Stage II...
